• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • PEGylated Drugs Companies

    ID: MRFR/Pharma/6964-CR
    173 Pages
    Rahul Gotadki
    July 2025

    PEGylation, the process of covalently attaching polyethylene glycol (PEG) to drugs, is a strategy used to improve the pharmacokinetic and pharmacodynamic properties of therapeutic agents. PEGylation can enhance the stability, solubility, and bioavailability of drugs, leading to improved therapeutic outcomes.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Pegylated Drugs Market Research Report – Forecast Till 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the PEGylated Drugs Market

    PEGylated Drugs Key CompaniesLatest PEGylated Drugs Companies Update



    • March 2023:

      A new GMP facility for the production of lipids for advanced pharmaceutical drug delivery applications has been established by Evonik at its location in Germany. In addition to the company's current laboratory and commercial production capacities, the 'lipid launch facility' can provide lipids for clinical and small-scale commercial manufacturing. Lipids manufactured on-site will be utilized in an extensive array of RNA and gene therapies, including protein replacement therapies, cancer immunotherapy, and infectious disease control. The lipid launch facility possessing particle engineering and purification capabilities, including chromatography, is capable of assisting clients in the manufacturing process of various types of proprietary and custom lipids. This includes phospholipids, ionizable cationic lipids, PEGylated lipids, and phospholipids.



    • August 2023:A biopharmaceutical company specializing in the production, development, and commercialization of recombinant therapeutic proteins generated via its proprietary ProCellEx® plant cell-based protein expression system, Protalix BioTherapeutics, Inc. disclosed financial results for the second quarter and furnished an update on recent corporate, regulatory, and clinical developments. Elfabrio® (pegunigalsidase alfa), a joint venture between the organization and its development and commercialization partner, Chiesi Global Rare Diseases (Chiesi), an organization of the Chiesi Group, has been granted regulatory approval in both the European Union (EU) and the United States (U.S.) for the management of Fabry disease in adult patients. The approved dosage is 1 mg^kg every two weeks. Elfabrio is a recombinant human α–Galactosidase–subtype enzyme replacement therapy (ERT) that is PEGylated.An enzyme engineered to possess an extended half-life and expressed in plant cell cultures. 


    List of PEGylated Drugs Key companies in the market

    • Horizon Therapeutics Plc

    • F. Hoffmann-La Roche Ltd. 

    • Pfizer Inc. 

    • Novo Nordisk A/S 

    • UCB S.A. 

    • Amgen, Inc. 

    • AstraZeneca.  


    • Merck & Co., Inc.  


    • Takeda Pharmaceutical Company Limited 

    • Bayer AG 

    • Biogen 

    • BioMarin Pharmaceutical Inc 

    • Coherus BioSciences • Enzon • Leadiant Biosciences, Inc.